Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
about
Multi-parametric MRI at 14T for muscular dystrophy mice treated with AAV vector-mediated gene therapyAdvances in gene therapy for muscular dystrophiesInvestigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular DystrophyThe Dystrophin Complex: Structure, Function, and Implications for TherapyAbnormal splicing switch of DMD's penultimate exon compromises muscle fibre maintenance in myotonic dystrophy.Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.Systemic Trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for duchenne muscular dystrophyImmune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging.Gene therapy progress and prospects: Duchenne muscular dystrophy.One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice.Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral VectorA 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.Analyzing cellular immunity to AAV in a canine model using ELISPOT assayTherapeutics in duchenne muscular dystrophy.Functional promoter testing using a modified lentiviral transfer vectorGene therapy in large animal models of muscular dystrophy.Gene therapy for muscular dystrophy: current progress and future prospects.Current Translational Research and Murine Models For Duchenne Muscular Dystrophy.AAV-directed muscular dystrophy gene therapy.Current advances in cell therapy strategies for muscular dystrophies.Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino.Dystrophin deficiency compromises force production of the extensor carpi ulnaris muscle in the canine model of Duchenne muscular dystrophy.Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy.A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples.
P2860
Q27308877-06F2D108-C2AD-40AE-99C7-73123FBC4D2FQ28073994-97D73BB5-7332-440C-A7DE-7CFA826795D9Q28598287-88E885F2-A849-49E0-A586-95330E8A7DFDQ30376293-9F26446B-DDD7-4C52-9C78-9E32055B4729Q30653577-619A462E-9BF4-4DC3-BDD2-2C01C5EBCCFAQ33690975-E36549E5-BF1D-4DAB-9A9E-1B1944D675F0Q33691883-AB7477D9-871E-4D9D-974F-33DAD2ECB1E3Q33731159-2BD84EF1-A25B-4F0B-8709-BF99A20AB443Q34576814-C4EC2106-F921-4669-BF0A-4F07E314FF7CQ34621772-3A1A073A-6B88-4F0B-9606-4D9E2A5454CCQ35513407-D7631E22-AE28-4564-8583-2C1782F51E6BQ35568505-5A867E07-53CA-4D46-AC68-143049E54B76Q35892390-72D52B06-81CF-4CEE-995B-7D36AE53BE90Q36428758-CE1DD51A-2C65-4963-BA49-8171AAB23B46Q37395618-46D1FFF3-598D-4B12-AE83-90724F9634EBQ37396408-3C826083-1B46-47F7-BEBC-ED1859E3208CQ37519650-E3AF18AD-0FFC-44DC-B8F3-5326017BCDD0Q37610505-A632E414-AF27-4E43-9C04-BCD1C5670CDEQ37687423-49EFD503-6CF8-4F93-BCD5-DDE82B1FAD31Q37827157-673B20CF-838C-41F5-B945-E22DDFDC10E3Q38829627-8C680E34-5ACF-449A-816B-6D80DCFF48EEQ39406545-0B39F054-6821-4F35-87C2-BC0A21C989A7Q40109350-83028BD9-5659-43DD-99A2-279DAC6F71EBQ42257279-0069899A-407E-4685-920A-A76BDE1DE01DQ42322829-84EF6A5C-0396-4929-9C8F-4B08FC5A5FB3Q45361267-9D520B4C-141A-46DE-8566-EB673390505AQ45888822-F7B9593A-1A29-44D4-A595-D7C6C3F6A8C9Q52564618-155B6DDA-B60C-4037-B129-D39DEFFED272Q52631121-0521D59D-0DE7-4519-B7A1-DC1FF67B6B35
P2860
Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Recombinant adeno-associated v ...... enne muscular dystrophy (DMD).
@ast
Recombinant adeno-associated v ...... enne muscular dystrophy (DMD).
@en
type
label
Recombinant adeno-associated v ...... enne muscular dystrophy (DMD).
@ast
Recombinant adeno-associated v ...... enne muscular dystrophy (DMD).
@en
prefLabel
Recombinant adeno-associated v ...... enne muscular dystrophy (DMD).
@ast
Recombinant adeno-associated v ...... enne muscular dystrophy (DMD).
@en
P2093
P2860
P356
P1433
P1476
Recombinant adeno-associated v ...... enne muscular dystrophy (DMD).
@en
P2093
Athanasopoulos T
P2860
P2888
P304
P356
10.1038/SJ.GT.3302379
P478
11 Suppl 1
P577
2004-10-01T00:00:00Z